Table H-4Strength of evidence for the comparative efficacy of omalizumab and placebo

Omalizumab compared with placebo
No. of studies (# of subjects)DesignQualityConsistencyDirectnessResults and magnitude of effectaOther modifying factorsaOverall strength of evidence
Overall total: Omalizumab compared with placebo
2 SRs (5,199)

8 RCTs (3480)
2 SR w/MA

6 RCTs
Good (1), Fair (1)

Good (2), Fair (6)
ConsistentDirectOM > placebo

Change in # of exacerbations per patient: WMD = −0.18, 95% CI: −0.24, −0.11

Percentage/number of patients with ≥ 1 exacerbation: OR = 0.51, 95% CI: 0.40, 0.67

Increase in AQLQ scores: SMD = 0.26, 95% CI: 0.18, 0.35

AQLQ = Asthma Quality of Life Questionnaire; CI = confidence interval; MA=meta-analysis; OM= Omalizumab; RCT= randomized controlled trial; SMD = standard mean difference; SR= systematic review.


Selected results from our meta-analyses of included RCTs; the complete meta-analyses is in Appendix I.

From: Appendix H, Strength of evidence

Cover of Drug Class Review: Controller Medications for Asthma
Drug Class Review: Controller Medications for Asthma: Final Update 1 Report [Internet].
Jonas DE, Wines RCM, DelMonte M, et al.
Portland (OR): Oregon Health & Science University; 2011 Apr.
Copyright © 2011 by Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.